SlideShare a Scribd company logo
© European Compliance Academy (ECA)
Developments in Regulatory
Requirements
Dr. Tim Sandle
European Microbiology Conference
4th
– 5th
May, Prague
© European Compliance Academy (ECA)
Introduction
 European Pharmacopoeia
 United States Pharmacopoeia
 ISO
 PIC/S
 EMEA
 FDA
 WHO
 ICH
 NHS
© European Compliance Academy (ECA)
Harmonisation
 USP, EP & JP: began in 1990
 Why harmonise?
• Globalisation of the pharmaceutical and associated industries
• Suppliers of raw materials operate globally for many products but need
locally adapted test methods, SOPs etc.
• Pharmaceutical manufacturers have to adapt test methods and
licensing files to local requirements
• Reduce costs
© European Compliance Academy (ECA)
European Pharmacopoeia
© European Compliance Academy (ECA)
European Pharmacopoeia
 European Pharmacopoeia is revised and issued by the
European Directorate for the Quality of Medicines &
HealthCare (EDQM) (Council of Europe)
• European Pharmacopoeia was first published in 1967
 European Pharmacopoeia is published in two volumes.
• The first volume consists of general chapters (such as the
sterility test) and the second of specific monographs for
materials (such as sodium heparin).
 European Pharmacopoeia is issued at periodic intervals.
• A primary edition.
• Several supplements over a two year period.
© European Compliance Academy (ECA)
European Pharmacopoeia
 Supplement 6.1: January 2008
 Supplement 6.2: January 2008
 Supplement 6.3: January 2008
 Supplement 6.4: June 2008
 Supplement 6.5: June 2008
 Supplement 6.6: July 2008
 Supplement 6.7: September 2009
 Supplement 6.8: January 2010
 7th
edition: January 2011
© European Compliance Academy (ECA)
European Pharmacopoeia
 Sterility Testing
• Supplement 6.3:
• New chapter 5.1.9 ‘Guidelines for using the test for sterility’
 Section of text deleted from 2.6.1
 To allow harmonisation with USP
 Relates to test method and method validation
• 2.6.1 is now almost fully harmonised with USP <71>
 Changes: precautions against microbial contamination, culture media and
incubation temperatures, method suitability test, main test method, minimum
number of items to be tested.
 “Residual differences” with USP: rinse fluids; volume of products tested;
number of containers of product to be tested; and acceptance criteria.
• Supplement 6.3:
• Reference added to indicate harmonization process
© European Compliance Academy (ECA)
European Pharmacopoeia
 Non-sterile products #1
• Supplement 6.3:
• Harmonisation with USP for:
» Microbiological examination of non-sterile products:
microbial enumeration tests (2.6.12)
» Microbial examination of non-sterile products: test for
specified micro-organisms (2.6.13)
» Microbial quality of non-sterile pharmaceutical preparations
and substances for pharmaceutical use (5.1.4)
- With 2.6.12 and 2.6.13, these chapters are now
interchangeable in the ICH regions (Q4B Annex 4A): JP & USP
© European Compliance Academy (ECA)
European Pharmacopoeia
 Non-sterile products #2
• Supplement 6.5:
 A negative control now required when verifying the
performance of the media AND also when testing products.
 With 2.6.13:
- E. coli has been deleted as an indicative strain for XLD agar
since it grows with difficulty on this medium
- Clostridia: the description of the test has been reworded Section
4-6-1 reads: “Divide the sample into 2 portions of at least 10
ml”. The wording has been included because a volume each of
the treated and of the untreated sample must be transferred to
a container with reinforced medium for clostridia.
- For any suspect positive Clostridia an ID test is required in
order to distinguish Clostridia from any facultative anaerobic
Bacillus species
© European Compliance Academy (ECA)
European Pharmacopoeia
Non-sterile products #3
 Supplement 6.5:
 2.6.13
 A maximum incubation time of 72 h has been added
(previous incubation time of exactly 48 h: too stringent)
 Recommended solutions and culture media: the
statement “Other media may be used if they have similar
growth promoting and inhibitory properties” has been
reworded because it had been considered misleading.
Revised wording:
“Other media may be used provided that their suitability
can be demonstrated”.
© European Compliance Academy (ECA)
European Pharmacopoeia
 Water testing
• Supplement 6.3:
• WFI 0169 and Purified Water 0008
 5-day incubation time has been replaced by a requirement of not
less than 5 days
 Addition of criteria for growth promotion of the R2A medium used for
microbiological monitoring (similar to media listed in 2.6.12 / 2.6.13)
© European Compliance Academy (ECA)
European Pharmacopoeia
 Bacterial Endotoxins (2.6.14)
• Supplement 6.6:
 A number of clarifications have been included.
- For the calculation of the endotoxin limit, the maximum
recommended concentration is no longer defined for a single
hour period but for a bolus dose.
 A new chapter ‘Test for bacterial endotoxins: guidelines’ (5.1.10).
- Not part of pharmacopoeial harmonisation
- Deleted from the 2.6.14 chapter and included in part 5 of the
European Pharmacopoeia.
© European Compliance Academy (ECA)
European Pharmacopoeia
 Pyrogens / Endotoxin
• For 7th
edition:
 General guidance
- EU Directive 86/609/EC
- Use of an in vitro method (the LAL test) as a preferred
alternative to the pyrogen test in rabbits for a number of
products (mainly blood products)
 2.6.14
- Gel-clot technique. The number 4 has been added to the
following statement:……”Determine the geometric mean end-
point concentration by calculating the mean of the logarithms of
the end-point concentrations of the 4 dilution series, take the
antilogarithm of this value, as indicated by the following
expression:………”
© European Compliance Academy (ECA)
European Pharmacopoeia
 New monograph: MAT
• Supplement 6.7:
• An new monograph has been published. This is 2.6.30 Monocyte-
activation test.
• The monocyte activation test (MAT) is possible replacement for the
rabbit pyrogen test and can potentially be used in conjunction with the
LAL test.
© European Compliance Academy (ECA)
European Pharmacopoeia
 Aspergillus brasiliensis
• Supplement 6.8:
 In relation to monographs 2.6.1 and 2.6.12
 Strain ATCC 16404, formerly Aspergillus niger has been
reclassified, following a polyphasic study, as Aspergillus brasiliensis
© European Compliance Academy (ECA)
European Pharmacopoeia
 2.6.21. Nucleic acid
amplification
techniques
• Supplement 6.8:
 A validation guideline for
the quantification of B19
virus DNA in plasma pools
© European Compliance Academy (ECA)
European Pharmacopoeia
 Biological Indicators
• For 7th
edition:
 Biological indicators (5.1.2)
 Names of organisms have been changed to be in line with current
taxonomic nomenclature
 Alignment with EN ISO 11138 (Sterilization of health care products -
Biological indicators)
© European Compliance Academy (ECA)
European Pharmacopoeia
 Revision of EP chapter 5.1.6. Alternative Methods for Control
of Microbiological Quality
• Describes alternative methods for the control of microbiological quality.
• Qualitative, quantitative and identification tests and guidance for using
validation criteria.
• Technology overviews including risk-benefit analysis and an annex
describing an example of a detailed protocol for the validation of an
alternative method using bioluminescence techniques.
© European Compliance Academy (ECA)
United States Pharmacopoeia
Recent changes
© European Compliance Academy (ECA)
United States Pharmacopoeia
USP33 2nd Supplement (October 2010)
<1072> Disinfectants and Antiseptics
 Classification of Disinfectants
 Selection of a Disinfectant for Use in a Pharmaceutical
Manufacturing Environment
 Theoretical Discussion of Disinfectant Activity
 Mechanism of Disinfectant Activity
 Microbial Resistance to Disinfectants
 Disinfectant Challenge Testing
 Disinfectants in a Cleaning and Sanitisation Program
© European Compliance Academy (ECA)
United States Pharmacopoeia
Proposed changes
© European Compliance Academy (ECA)
United States Pharmacopoeia
 USP <1231> ‘water’
• Under revision
• Tables of
recommendation
action limits are likely
to be deleted
© European Compliance Academy (ECA)
United States Pharmacopoeia
 USP <1116> under
review
• Action levels for EM
likely to be replaced by
frequency tables
 E.g. Isolator, incidence
rate of <0.1%
 E.g. ISO Class 5,
incidence rate of <1%
© European Compliance Academy (ECA)
United States Pharmacopoeia
 USP <1113> Microbial Identification (USP35-NF30)
• Title change
• Microbial Characterization, Identification, and Strain Typing
• The chapter provides general information on available microbial
identification methods, selection of appropriate methods for use, and
verification of these methods
• Emphasis on phenotypic and genotypic methods
• Trending microflora
© European Compliance Academy (ECA)
United States Pharmacopoeia
 <85> Bacterial Endotoxins Test
• on the basis of an FDA recommendation, change the
calculation of the limit for endotoxins in products
dosed by body surface area, appearing in non
harmonized footnote 2
© European Compliance Academy (ECA)
United States Pharmacopoeia
Possible changes
© European Compliance Academy (ECA)
United States Pharmacopoeia
 A new monograph entitled, “Endotoxin Indicator for
Depyrogenation” was proposed in Pharmacopeial
Forum (34(6): 1444).
• Definition of the term endotoxin indicator - “carrier (challenge vial of
endotoxin or an article spiked with endotoxin) for use in depyrogenation
studies.”
• Description of the characterization (identification, purity) of an EI
 Also:
• Reference to the USP RSE
• Packaging and storage
• Expiration dating
• Recovery tests
• Disposal of endotoxin indicators.
© European Compliance Academy (ECA)
United States Pharmacopoeia
 <1128> Nucleic Acid Based Techniques –
Microarray (new) (USP35-NF30)
• Because there is no information in USP on this subject, this
general information chapter is being proposed.
• This new chapter is a part of the series of information chapters
describing various aspects of nucleic acid-based testing:
 <1125> Nucleic Acid Based Techniques-General
 <1126> Nucleic Acid Based Techniques-Extraction, Detection and
Sequencing
 <1127> Nucleic Acid Based Techniques-Amplification
 <1129> Nucleic Acid Based Techniques-Genotyping
 <1130> Nucleic Acid Based Techniques-Approaches for detecting
Trace Nucleic Acids (Residual DNA Testing)
© European Compliance Academy (ECA)
ISO standards
© European Compliance Academy (ECA)
ISO
ISO14968 (under review)
Standard ISO14698 (Bio contamination control) is currently under
review by British Standards
 Part 1 General principles and methods
 Part 2 Evaluation and interpretation of biocontamiantion data
Aims:
 Classification of cleanrooms by airborne biocontamination,
including methods of measurement and the validation of
sampling methods. Similar to ISO14644
 Approaches to classify and monitor cleanroom surfaces.
 Risk management and assessment techniques.
 Establish a relationship between enumeration and the types of
isolates detected
 Consideration of some of the weaknesses of environmental
monitoring sampling methods
© European Compliance Academy (ECA)
ISO
 ISO 14644 (under review)
• Primary change proposed is a new method for cleanroom classification
• Current standard determines the number of particle counter locations in
a cleanroom using a formula based on the square root of the surface
area of the cleanroom in cubic metres.
• The proposed change is move to classification using a table with a
formula for intermediate classes (a ‘return’ to the old FS209E).
© European Compliance Academy (ECA)
ISO
 ISO 21501 (in place)
• Calibration of particle counters
 Size calibration
 Verification of size setting
 Counting efficiency
 Size resolution
 False count rate
 Concentration limit
 Sampling flow rate
 Sampling time
 Sampling volume
• Many older model particle counters will not meet the new standard.
© European Compliance Academy (ECA)
PIC/S and EMA
© European Compliance Academy (ECA)
PIC/S
 PIC/S inspection guides
• ‘Validation of Aseptic Processes’ (PI 007-5)
 That media fills should be run for a similar length of time as product fills;
 The number of containers filled should be close to the commercial
batch size;
 The frequency of re-qualifications is a minimum of six-monthly;
 There is considerable emphasis on the selection of the appropriate
culture medium, including being able to demonstrate growth promotion
(as an aside, due to concerns with TSEs in Europe some companies
have moved away from bovine based media and towards vegetable
peptones);
 The incubation conditions are established as:
- “incubate at 20-25°C for a minimum of 7 days followed
immediately, or after a first reading, by incubation at 30-35°C for a
total minimum incubation time of 14 days”
© European Compliance Academy (ECA)
PIC/S
 PIC/S inspection guides
• PIC/S Document 007-4 ‘Recommendation on the Validation of aseptic
processes’ has been updated
• PIC/S guidance on EU GMP Annex 1
 Cleanrooms and clean air device classification; and media simulation trials.
© European Compliance Academy (ECA)
EMA
 The EMA has published some questions and answers concerning
the use of Process Analytical Technology (PAT) on their website:
http://www.gmp-compliance.org/eca_news_1385_5940,6080,6077,6095,6
© European Compliance Academy (ECA)
FDA
© European Compliance Academy (ECA)
FDA
 FDA draft Process Validation Guidance
• FDA’s current thinking on process manufacture
• Reference to ICH Q8, Q9 and Q10, particularly the product lifecycle
approach.
• Main sections : process design, process qualification and continued
process verification.
© European Compliance Academy (ECA)
FDA
 The FDA have
‘adopted’:
• three annex
documents to ICH
Q4B (4A, 4B and 4C).
• The annexes relate to
the microbiological
control of non-sterile
doses.
© European Compliance Academy (ECA)
WHO and NHS
© European Compliance Academy (ECA)
WHO
 New publications / updates:
• ‘WHO Expert Committee on Specifications for Pharmaceutical
Preparations’.
• WHO Good Practices for Pharmaceutical Quality Control Laboratories
 Guide to:
- Management, infrastructure, materials, working procedures, and safety
• Annex 4 “Good Manufacturing Practices for Sterile Pharmaceutical
Products”
 To come in line with ISO 14644-1
© European Compliance Academy (ECA)
NHS
 Monitoring hospital and cleanroom gowns
• The UK NHS have a useful illustrated guide to monitoring cleanroom
gowns for hospital pharmacies (EU GMP Grade B environments). The
guide contains some useful pointers about selecting the locations for
the microbiological contact plate monitoring and frequencies of testing.
© European Compliance Academy (ECA)
Thank You
www.pharmig.blogspot.com

More Related Content

What's hot

Temperature controlled transport according to current EU GDP
Temperature controlled transport according to current EU GDPTemperature controlled transport according to current EU GDP
Temperature controlled transport according to current EU GDP
Pauwels Consulting
 
Deviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPADeviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPA
Dr. Amsavel A
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
Compliance Insight, Inc.
 
Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...
Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...
Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...
Akash Saini
 
Line clearance basic
Line clearance basicLine clearance basic
Line clearance basic
Md Mosaruf Hossan
 
Packaging material vendor audit
Packaging material vendor auditPackaging material vendor audit
Packaging material vendor audit
RavichandraNadagouda
 
Control on Cleanroom Environmental Monitoring (Pharmaceutical)
Control on Cleanroom Environmental Monitoring (Pharmaceutical)Control on Cleanroom Environmental Monitoring (Pharmaceutical)
Control on Cleanroom Environmental Monitoring (Pharmaceutical)
Srinath Sasidharan
 
Gmp Guidelines by HCP
Gmp Guidelines by HCPGmp Guidelines by HCP
Gmp Guidelines by HCP
Atlantic Training, LLC.
 
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science IndustryFda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industry
dmanalan
 
Gmp Auditor Training Course
Gmp Auditor   Training CourseGmp Auditor   Training Course
Gmp Auditor Training Course
piyush64173
 
GMP (Good Manufacturing Practice) presentation
GMP (Good Manufacturing Practice) presentation GMP (Good Manufacturing Practice) presentation
GMP (Good Manufacturing Practice) presentation
Durrani Yousuf Khan
 
Principles of Aseptic Processing
Principles of Aseptic ProcessingPrinciples of Aseptic Processing
Principles of Aseptic Processing
NSF Health Sciences
 
Pharmaceutical Data integrity training
Pharmaceutical Data integrity trainingPharmaceutical Data integrity training
Pharmaceutical Data integrity training
Moataz El Halawany
 
Cross contamination in Pharmaceuticals - by Jitendra J Jagtap
Cross contamination in Pharmaceuticals - by Jitendra J JagtapCross contamination in Pharmaceuticals - by Jitendra J Jagtap
Cross contamination in Pharmaceuticals - by Jitendra J Jagtap
jitendrajagtap1986
 
Master batch record,batch production record ,Quality Audit Type and plan &Rec...
Master batch record,batch production record ,Quality Audit Type and plan &Rec...Master batch record,batch production record ,Quality Audit Type and plan &Rec...
Master batch record,batch production record ,Quality Audit Type and plan &Rec...
KarishmaFuse
 
Container closure system and issues facing modern drug packaging
Container closure system and issues facing modern drug packagingContainer closure system and issues facing modern drug packaging
Container closure system and issues facing modern drug packaging
PrathameshSarda1
 
GMP
GMP GMP
Out of specifications
Out of specificationsOut of specifications
Out of specifications
Hossen M. Faruk
 
Qualification and validation - WHO GMP training
Qualification and validation - WHO GMP trainingQualification and validation - WHO GMP training
GDP Training NS
GDP Training NSGDP Training NS
GDP Training NS
Neeraj Shrivastava
 

What's hot (20)

Temperature controlled transport according to current EU GDP
Temperature controlled transport according to current EU GDPTemperature controlled transport according to current EU GDP
Temperature controlled transport according to current EU GDP
 
Deviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPADeviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPA
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
 
Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...
Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...
Good manufacturing practices (gmp) Akash Saini (Dr. H. S. Gour University, Sa...
 
Line clearance basic
Line clearance basicLine clearance basic
Line clearance basic
 
Packaging material vendor audit
Packaging material vendor auditPackaging material vendor audit
Packaging material vendor audit
 
Control on Cleanroom Environmental Monitoring (Pharmaceutical)
Control on Cleanroom Environmental Monitoring (Pharmaceutical)Control on Cleanroom Environmental Monitoring (Pharmaceutical)
Control on Cleanroom Environmental Monitoring (Pharmaceutical)
 
Gmp Guidelines by HCP
Gmp Guidelines by HCPGmp Guidelines by HCP
Gmp Guidelines by HCP
 
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science IndustryFda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industry
 
Gmp Auditor Training Course
Gmp Auditor   Training CourseGmp Auditor   Training Course
Gmp Auditor Training Course
 
GMP (Good Manufacturing Practice) presentation
GMP (Good Manufacturing Practice) presentation GMP (Good Manufacturing Practice) presentation
GMP (Good Manufacturing Practice) presentation
 
Principles of Aseptic Processing
Principles of Aseptic ProcessingPrinciples of Aseptic Processing
Principles of Aseptic Processing
 
Pharmaceutical Data integrity training
Pharmaceutical Data integrity trainingPharmaceutical Data integrity training
Pharmaceutical Data integrity training
 
Cross contamination in Pharmaceuticals - by Jitendra J Jagtap
Cross contamination in Pharmaceuticals - by Jitendra J JagtapCross contamination in Pharmaceuticals - by Jitendra J Jagtap
Cross contamination in Pharmaceuticals - by Jitendra J Jagtap
 
Master batch record,batch production record ,Quality Audit Type and plan &Rec...
Master batch record,batch production record ,Quality Audit Type and plan &Rec...Master batch record,batch production record ,Quality Audit Type and plan &Rec...
Master batch record,batch production record ,Quality Audit Type and plan &Rec...
 
Container closure system and issues facing modern drug packaging
Container closure system and issues facing modern drug packagingContainer closure system and issues facing modern drug packaging
Container closure system and issues facing modern drug packaging
 
GMP
GMP GMP
GMP
 
Out of specifications
Out of specificationsOut of specifications
Out of specifications
 
Qualification and validation - WHO GMP training
Qualification and validation - WHO GMP trainingQualification and validation - WHO GMP training
Qualification and validation - WHO GMP training
 
GDP Training NS
GDP Training NSGDP Training NS
GDP Training NS
 

Viewers also liked

Black Death and plague: a new understanding
Black Death and plague: a new understandingBlack Death and plague: a new understanding
Black Death and plague: a new understanding
Tim Sandle, Ph.D.
 
Application of microbiological data
Application of microbiological dataApplication of microbiological data
Application of microbiological data
Tim Sandle, Ph.D.
 
Cleanroom history
Cleanroom historyCleanroom history
Cleanroom history
Tim Sandle, Ph.D.
 
The Black death - a re-emerging infectious disease
The Black death - a re-emerging infectious diseaseThe Black death - a re-emerging infectious disease
The Black death - a re-emerging infectious disease
Tim Sandle, Ph.D.
 
Risk analysis in sterile operation
Risk analysis in sterile operationRisk analysis in sterile operation
Risk analysis in sterile operation
Tim Sandle, Ph.D.
 
Myths of pharmaceutical microbiology
Myths of pharmaceutical microbiologyMyths of pharmaceutical microbiology
Myths of pharmaceutical microbiology
Tim Sandle, Ph.D.
 
USP &lt;1116> and its impact on Microbiology
USP &lt;1116> and its impact on MicrobiologyUSP &lt;1116> and its impact on Microbiology
USP &lt;1116> and its impact on Microbiology
Tim Sandle, Ph.D.
 
Sterility assurance
Sterility assuranceSterility assurance
Sterility assurance
Tim Sandle, Ph.D.
 
Risk Management in Sterile Environments
Risk Management in Sterile Environments Risk Management in Sterile Environments
Risk Management in Sterile Environments
Tim Sandle, Ph.D.
 
Lal presentation
Lal presentation Lal presentation
Lal presentation
Tim Sandle, Ph.D.
 
Depyrogenation by dry heat
Depyrogenation by dry heatDepyrogenation by dry heat
Depyrogenation by dry heat
Tim Sandle, Ph.D.
 
ISO 14644 - introducing the revised standard
ISO 14644 - introducing the revised standardISO 14644 - introducing the revised standard
ISO 14644 - introducing the revised standard
Tim Sandle, Ph.D.
 
Cleanroom sop slides
Cleanroom sop slidesCleanroom sop slides
Cleanroom sop slides
Tim Sandle, Ph.D.
 
EU GMP Annex1 Review
EU GMP Annex1 ReviewEU GMP Annex1 Review
EU GMP Annex1 Review
Tim Sandle, Ph.D.
 
Toc analyser, microprocessor controlled
Toc analyser, microprocessor controlledToc analyser, microprocessor controlled
Toc analyser, microprocessor controlled
hydrologyproject0
 
Water treatment
Water treatmentWater treatment
In-House Microbial Isolates in Compendial Testing: Regulatory Requirements
In-House Microbial Isolates in Compendial Testing: Regulatory RequirementsIn-House Microbial Isolates in Compendial Testing: Regulatory Requirements
In-House Microbial Isolates in Compendial Testing: Regulatory Requirements
Robert Westney
 
Service improvement in microbiology: why, what and how
Service improvement in microbiology: why, what and howService improvement in microbiology: why, what and how
Service improvement in microbiology: why, what and how
NHS Improvement
 
Objectionable microorganisms within and beyond regulations
Objectionable microorganisms within and beyond regulationsObjectionable microorganisms within and beyond regulations
Objectionable microorganisms within and beyond regulations
Stephen Mc Grath PhD
 
Water system , IMPORTANCE OF WATER & Water Treatment
Water system , IMPORTANCE OF WATER & Water Treatment Water system , IMPORTANCE OF WATER & Water Treatment
Water system , IMPORTANCE OF WATER & Water Treatment
ICHAPPS
 

Viewers also liked (20)

Black Death and plague: a new understanding
Black Death and plague: a new understandingBlack Death and plague: a new understanding
Black Death and plague: a new understanding
 
Application of microbiological data
Application of microbiological dataApplication of microbiological data
Application of microbiological data
 
Cleanroom history
Cleanroom historyCleanroom history
Cleanroom history
 
The Black death - a re-emerging infectious disease
The Black death - a re-emerging infectious diseaseThe Black death - a re-emerging infectious disease
The Black death - a re-emerging infectious disease
 
Risk analysis in sterile operation
Risk analysis in sterile operationRisk analysis in sterile operation
Risk analysis in sterile operation
 
Myths of pharmaceutical microbiology
Myths of pharmaceutical microbiologyMyths of pharmaceutical microbiology
Myths of pharmaceutical microbiology
 
USP &lt;1116> and its impact on Microbiology
USP &lt;1116> and its impact on MicrobiologyUSP &lt;1116> and its impact on Microbiology
USP &lt;1116> and its impact on Microbiology
 
Sterility assurance
Sterility assuranceSterility assurance
Sterility assurance
 
Risk Management in Sterile Environments
Risk Management in Sterile Environments Risk Management in Sterile Environments
Risk Management in Sterile Environments
 
Lal presentation
Lal presentation Lal presentation
Lal presentation
 
Depyrogenation by dry heat
Depyrogenation by dry heatDepyrogenation by dry heat
Depyrogenation by dry heat
 
ISO 14644 - introducing the revised standard
ISO 14644 - introducing the revised standardISO 14644 - introducing the revised standard
ISO 14644 - introducing the revised standard
 
Cleanroom sop slides
Cleanroom sop slidesCleanroom sop slides
Cleanroom sop slides
 
EU GMP Annex1 Review
EU GMP Annex1 ReviewEU GMP Annex1 Review
EU GMP Annex1 Review
 
Toc analyser, microprocessor controlled
Toc analyser, microprocessor controlledToc analyser, microprocessor controlled
Toc analyser, microprocessor controlled
 
Water treatment
Water treatmentWater treatment
Water treatment
 
In-House Microbial Isolates in Compendial Testing: Regulatory Requirements
In-House Microbial Isolates in Compendial Testing: Regulatory RequirementsIn-House Microbial Isolates in Compendial Testing: Regulatory Requirements
In-House Microbial Isolates in Compendial Testing: Regulatory Requirements
 
Service improvement in microbiology: why, what and how
Service improvement in microbiology: why, what and howService improvement in microbiology: why, what and how
Service improvement in microbiology: why, what and how
 
Objectionable microorganisms within and beyond regulations
Objectionable microorganisms within and beyond regulationsObjectionable microorganisms within and beyond regulations
Objectionable microorganisms within and beyond regulations
 
Water system , IMPORTANCE OF WATER & Water Treatment
Water system , IMPORTANCE OF WATER & Water Treatment Water system , IMPORTANCE OF WATER & Water Treatment
Water system , IMPORTANCE OF WATER & Water Treatment
 

Similar to Developments in regulatory requirements

Automated release of water using on line TOC analysis and FDA risk-based cGMP...
Automated release of water using on line TOC analysis and FDA risk-based cGMP...Automated release of water using on line TOC analysis and FDA risk-based cGMP...
Automated release of water using on line TOC analysis and FDA risk-based cGMP...
Jalis Muktadir
 
ICH GUIDELINE Q 23024671010_RA.pptx
ICH GUIDELINE Q      23024671010_RA.pptxICH GUIDELINE Q      23024671010_RA.pptx
ICH GUIDELINE Q 23024671010_RA.pptx
70KRISHPATEL
 
ICH- Objectives and stability guidelines
ICH- Objectives and stability guidelinesICH- Objectives and stability guidelines
ICH- Objectives and stability guidelines
JaskiranKaur72
 
ICH [ Q ] Guidelines
ICH [ Q ] GuidelinesICH [ Q ] Guidelines
ICH [ Q ] Guidelines
AbhishekPatil387
 
special emphasis on Q series guidelines
special emphasis on Q series guidelines special emphasis on Q series guidelines
special emphasis on Q series guidelines
srikrupa institute of pharmaceutical analysis
 
ICH
ICHICH
VICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptxVICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptx
ssuser796efb
 
ICH Guidelines.pdf
ICH Guidelines.pdfICH Guidelines.pdf
ICH Guidelines.pdf
MohdFaisal722315
 
Ich Guidelines Au. Vivek Jain
Ich Guidelines Au. Vivek JainIch Guidelines Au. Vivek Jain
Ich Guidelines Au. Vivek Jain
Vivek Jain
 
Master of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH GiudelinesMaster of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH Giudelines
omkarmandlik678
 
ICH Guidelines with details of ICH Q3 Guidelines
ICH Guidelines with details of ICH Q3 GuidelinesICH Guidelines with details of ICH Q3 Guidelines
ICH Guidelines with details of ICH Q3 Guidelines
Prabhjot kaur
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
KoriyaKrupali1
 
Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...
Peter van Amsterdam
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)
Surendra Singh
 
ICH guideline.pdf
ICH guideline.pdfICH guideline.pdf
ICH guideline.pdf
Zeelshah2258
 
ichguidelines_Final.ppt
ichguidelines_Final.pptichguidelines_Final.ppt
ichguidelines_Final.ppt
TridevSastri1
 
Ich
IchIch
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
Peter van Amsterdam
 
usp1116presmar2016-160306010258.pptx
usp1116presmar2016-160306010258.pptxusp1116presmar2016-160306010258.pptx
usp1116presmar2016-160306010258.pptx
Balaji Kuzhandhaivelu
 
ICH guidelines
ICH guidelinesICH guidelines
ICH guidelines
Koshish Gabhane
 

Similar to Developments in regulatory requirements (20)

Automated release of water using on line TOC analysis and FDA risk-based cGMP...
Automated release of water using on line TOC analysis and FDA risk-based cGMP...Automated release of water using on line TOC analysis and FDA risk-based cGMP...
Automated release of water using on line TOC analysis and FDA risk-based cGMP...
 
ICH GUIDELINE Q 23024671010_RA.pptx
ICH GUIDELINE Q      23024671010_RA.pptxICH GUIDELINE Q      23024671010_RA.pptx
ICH GUIDELINE Q 23024671010_RA.pptx
 
ICH- Objectives and stability guidelines
ICH- Objectives and stability guidelinesICH- Objectives and stability guidelines
ICH- Objectives and stability guidelines
 
ICH [ Q ] Guidelines
ICH [ Q ] GuidelinesICH [ Q ] Guidelines
ICH [ Q ] Guidelines
 
special emphasis on Q series guidelines
special emphasis on Q series guidelines special emphasis on Q series guidelines
special emphasis on Q series guidelines
 
ICH
ICHICH
ICH
 
VICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptxVICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptx
 
ICH Guidelines.pdf
ICH Guidelines.pdfICH Guidelines.pdf
ICH Guidelines.pdf
 
Ich Guidelines Au. Vivek Jain
Ich Guidelines Au. Vivek JainIch Guidelines Au. Vivek Jain
Ich Guidelines Au. Vivek Jain
 
Master of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH GiudelinesMaster of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH Giudelines
 
ICH Guidelines with details of ICH Q3 Guidelines
ICH Guidelines with details of ICH Q3 GuidelinesICH Guidelines with details of ICH Q3 Guidelines
ICH Guidelines with details of ICH Q3 Guidelines
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
 
Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)
 
ICH guideline.pdf
ICH guideline.pdfICH guideline.pdf
ICH guideline.pdf
 
ichguidelines_Final.ppt
ichguidelines_Final.pptichguidelines_Final.ppt
ichguidelines_Final.ppt
 
Ich
IchIch
Ich
 
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
 
usp1116presmar2016-160306010258.pptx
usp1116presmar2016-160306010258.pptxusp1116presmar2016-160306010258.pptx
usp1116presmar2016-160306010258.pptx
 
ICH guidelines
ICH guidelinesICH guidelines
ICH guidelines
 

More from Tim Sandle, Ph.D.

Reviewing environmental monitoring.ppt
Reviewing environmental monitoring.pptReviewing environmental monitoring.ppt
Reviewing environmental monitoring.ppt
Tim Sandle, Ph.D.
 
Open discussion on rapid microbiological methods.pptx
Open discussion on rapid microbiological methods.pptxOpen discussion on rapid microbiological methods.pptx
Open discussion on rapid microbiological methods.pptx
Tim Sandle, Ph.D.
 
Electronic Data Management Systems.ppt
Electronic Data Management Systems.pptElectronic Data Management Systems.ppt
Electronic Data Management Systems.ppt
Tim Sandle, Ph.D.
 
Risk management and environmental monitoring
Risk management and environmental monitoringRisk management and environmental monitoring
Risk management and environmental monitoring
Tim Sandle, Ph.D.
 
Audit efficiency storyboard.pptx
Audit efficiency storyboard.pptxAudit efficiency storyboard.pptx
Audit efficiency storyboard.pptx
Tim Sandle, Ph.D.
 
Anomalies, complaints and non-compliances
Anomalies, complaints and non-compliancesAnomalies, complaints and non-compliances
Anomalies, complaints and non-compliances
Tim Sandle, Ph.D.
 
Pharma micro myths (sandle)
Pharma micro myths (sandle)Pharma micro myths (sandle)
Pharma micro myths (sandle)
Tim Sandle, Ph.D.
 
Application of FMEA to a Sterility Testing Isolator: A Case Study
Application of FMEA to a Sterility Testing Isolator: A Case StudyApplication of FMEA to a Sterility Testing Isolator: A Case Study
Application of FMEA to a Sterility Testing Isolator: A Case Study
Tim Sandle, Ph.D.
 
Operation of Sterility Testing Isolators and validation issues
Operation of Sterility Testing Isolators and validation issuesOperation of Sterility Testing Isolators and validation issues
Operation of Sterility Testing Isolators and validation issues
Tim Sandle, Ph.D.
 
Pharmaceutical Microbiology: Current and Future Challenges
Pharmaceutical Microbiology: Current and Future Challenges Pharmaceutical Microbiology: Current and Future Challenges
Pharmaceutical Microbiology: Current and Future Challenges
Tim Sandle, Ph.D.
 
The selection and use of reference materials
The selection and use of reference materialsThe selection and use of reference materials
The selection and use of reference materials
Tim Sandle, Ph.D.
 
Sterility assurance and microbiology awareness
Sterility assurance and microbiology awarenessSterility assurance and microbiology awareness
Sterility assurance and microbiology awareness
Tim Sandle, Ph.D.
 
Introduction to GxP
Introduction to GxPIntroduction to GxP
Introduction to GxP
Tim Sandle, Ph.D.
 

More from Tim Sandle, Ph.D. (13)

Reviewing environmental monitoring.ppt
Reviewing environmental monitoring.pptReviewing environmental monitoring.ppt
Reviewing environmental monitoring.ppt
 
Open discussion on rapid microbiological methods.pptx
Open discussion on rapid microbiological methods.pptxOpen discussion on rapid microbiological methods.pptx
Open discussion on rapid microbiological methods.pptx
 
Electronic Data Management Systems.ppt
Electronic Data Management Systems.pptElectronic Data Management Systems.ppt
Electronic Data Management Systems.ppt
 
Risk management and environmental monitoring
Risk management and environmental monitoringRisk management and environmental monitoring
Risk management and environmental monitoring
 
Audit efficiency storyboard.pptx
Audit efficiency storyboard.pptxAudit efficiency storyboard.pptx
Audit efficiency storyboard.pptx
 
Anomalies, complaints and non-compliances
Anomalies, complaints and non-compliancesAnomalies, complaints and non-compliances
Anomalies, complaints and non-compliances
 
Pharma micro myths (sandle)
Pharma micro myths (sandle)Pharma micro myths (sandle)
Pharma micro myths (sandle)
 
Application of FMEA to a Sterility Testing Isolator: A Case Study
Application of FMEA to a Sterility Testing Isolator: A Case StudyApplication of FMEA to a Sterility Testing Isolator: A Case Study
Application of FMEA to a Sterility Testing Isolator: A Case Study
 
Operation of Sterility Testing Isolators and validation issues
Operation of Sterility Testing Isolators and validation issuesOperation of Sterility Testing Isolators and validation issues
Operation of Sterility Testing Isolators and validation issues
 
Pharmaceutical Microbiology: Current and Future Challenges
Pharmaceutical Microbiology: Current and Future Challenges Pharmaceutical Microbiology: Current and Future Challenges
Pharmaceutical Microbiology: Current and Future Challenges
 
The selection and use of reference materials
The selection and use of reference materialsThe selection and use of reference materials
The selection and use of reference materials
 
Sterility assurance and microbiology awareness
Sterility assurance and microbiology awarenessSterility assurance and microbiology awareness
Sterility assurance and microbiology awareness
 
Introduction to GxP
Introduction to GxPIntroduction to GxP
Introduction to GxP
 

Recently uploaded

Bragg Brentano Alignment for D4 with LynxEye Rev3.pptx
Bragg Brentano Alignment for D4 with LynxEye Rev3.pptxBragg Brentano Alignment for D4 with LynxEye Rev3.pptx
Bragg Brentano Alignment for D4 with LynxEye Rev3.pptx
Lisandro Cunci
 
Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...
Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...
Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...
Sérgio Sacani
 
A slightly oblate dark matter halo revealed by a retrograde precessing Galact...
A slightly oblate dark matter halo revealed by a retrograde precessing Galact...A slightly oblate dark matter halo revealed by a retrograde precessing Galact...
A slightly oblate dark matter halo revealed by a retrograde precessing Galact...
Sérgio Sacani
 
poikilocytosis 23765437865210857453257844.pptx
poikilocytosis 23765437865210857453257844.pptxpoikilocytosis 23765437865210857453257844.pptx
poikilocytosis 23765437865210857453257844.pptx
muralinath2
 
BIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptx
BIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptxBIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptx
BIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptx
alishyt102010
 
Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...
Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...
Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...
Sérgio Sacani
 
Liver & Gall Bladder 23098463278654387654328765439875.pptx
Liver & Gall Bladder 23098463278654387654328765439875.pptxLiver & Gall Bladder 23098463278654387654328765439875.pptx
Liver & Gall Bladder 23098463278654387654328765439875.pptx
muralinath2
 
Dalghren, Thorne and Stebbins System of Classification of Angiosperms
Dalghren, Thorne and Stebbins System of Classification of AngiospermsDalghren, Thorne and Stebbins System of Classification of Angiosperms
Dalghren, Thorne and Stebbins System of Classification of Angiosperms
Gurjant Singh
 
Active and Passive Surveillance of pharmacovigillance
Active and Passive Surveillance of pharmacovigillanceActive and Passive Surveillance of pharmacovigillance
Active and Passive Surveillance of pharmacovigillance
SejalAgrawal43
 
Science-Technology Quiz (School Quiz 2024)
Science-Technology Quiz (School Quiz 2024)Science-Technology Quiz (School Quiz 2024)
Science-Technology Quiz (School Quiz 2024)
Kashyap J
 
The Dynamical Origins of the Dark Comets and a Proposed Evolutionary Track
The Dynamical Origins of the Dark Comets and a Proposed Evolutionary TrackThe Dynamical Origins of the Dark Comets and a Proposed Evolutionary Track
The Dynamical Origins of the Dark Comets and a Proposed Evolutionary Track
Sérgio Sacani
 
[1] Data Mining - Concepts and Techniques (3rd Ed).pdf
[1] Data Mining - Concepts and Techniques (3rd Ed).pdf[1] Data Mining - Concepts and Techniques (3rd Ed).pdf
[1] Data Mining - Concepts and Techniques (3rd Ed).pdf
PANDURANGLAWATE1
 
Gasification and Pyrolyssis of plastic Waste under a Circular Economy perpective
Gasification and Pyrolyssis of plastic Waste under a Circular Economy perpectiveGasification and Pyrolyssis of plastic Waste under a Circular Economy perpective
Gasification and Pyrolyssis of plastic Waste under a Circular Economy perpective
Recupera
 
Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...
Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...
Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...
University of Maribor
 
Anatomy, and reproduction of Gnetum.pptx
Anatomy, and reproduction of Gnetum.pptxAnatomy, and reproduction of Gnetum.pptx
Anatomy, and reproduction of Gnetum.pptx
karthiksaran8
 
SCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptx
SCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptxSCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptx
SCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptx
JoanaBanasen1
 
The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...
The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...
The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...
Sérgio Sacani
 
Gametogenesis: Male gametes Formation Process / Spermatogenesis .pdf
Gametogenesis: Male gametes Formation Process / Spermatogenesis .pdfGametogenesis: Male gametes Formation Process / Spermatogenesis .pdf
Gametogenesis: Male gametes Formation Process / Spermatogenesis .pdf
SELF-EXPLANATORY
 
El Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdf
El Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdfEl Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdf
El Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdf
Champs Elysee Roldan
 
HAZARDOUS ENERGIES -LOTO Training Program.pptx
HAZARDOUS ENERGIES -LOTO Training Program.pptxHAZARDOUS ENERGIES -LOTO Training Program.pptx
HAZARDOUS ENERGIES -LOTO Training Program.pptx
ArfanSubhani
 

Recently uploaded (20)

Bragg Brentano Alignment for D4 with LynxEye Rev3.pptx
Bragg Brentano Alignment for D4 with LynxEye Rev3.pptxBragg Brentano Alignment for D4 with LynxEye Rev3.pptx
Bragg Brentano Alignment for D4 with LynxEye Rev3.pptx
 
Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...
Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...
Transmission Spectroscopy of the Habitable Zone Exoplanet LHS 1140 b with JWS...
 
A slightly oblate dark matter halo revealed by a retrograde precessing Galact...
A slightly oblate dark matter halo revealed by a retrograde precessing Galact...A slightly oblate dark matter halo revealed by a retrograde precessing Galact...
A slightly oblate dark matter halo revealed by a retrograde precessing Galact...
 
poikilocytosis 23765437865210857453257844.pptx
poikilocytosis 23765437865210857453257844.pptxpoikilocytosis 23765437865210857453257844.pptx
poikilocytosis 23765437865210857453257844.pptx
 
BIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptx
BIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptxBIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptx
BIOPHYSICS Interactions of molecules in 3-D space-determining binding and.pptx
 
Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...
Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...
Possible Anthropogenic Contributions to the LAMP-observed Surficial Icy Regol...
 
Liver & Gall Bladder 23098463278654387654328765439875.pptx
Liver & Gall Bladder 23098463278654387654328765439875.pptxLiver & Gall Bladder 23098463278654387654328765439875.pptx
Liver & Gall Bladder 23098463278654387654328765439875.pptx
 
Dalghren, Thorne and Stebbins System of Classification of Angiosperms
Dalghren, Thorne and Stebbins System of Classification of AngiospermsDalghren, Thorne and Stebbins System of Classification of Angiosperms
Dalghren, Thorne and Stebbins System of Classification of Angiosperms
 
Active and Passive Surveillance of pharmacovigillance
Active and Passive Surveillance of pharmacovigillanceActive and Passive Surveillance of pharmacovigillance
Active and Passive Surveillance of pharmacovigillance
 
Science-Technology Quiz (School Quiz 2024)
Science-Technology Quiz (School Quiz 2024)Science-Technology Quiz (School Quiz 2024)
Science-Technology Quiz (School Quiz 2024)
 
The Dynamical Origins of the Dark Comets and a Proposed Evolutionary Track
The Dynamical Origins of the Dark Comets and a Proposed Evolutionary TrackThe Dynamical Origins of the Dark Comets and a Proposed Evolutionary Track
The Dynamical Origins of the Dark Comets and a Proposed Evolutionary Track
 
[1] Data Mining - Concepts and Techniques (3rd Ed).pdf
[1] Data Mining - Concepts and Techniques (3rd Ed).pdf[1] Data Mining - Concepts and Techniques (3rd Ed).pdf
[1] Data Mining - Concepts and Techniques (3rd Ed).pdf
 
Gasification and Pyrolyssis of plastic Waste under a Circular Economy perpective
Gasification and Pyrolyssis of plastic Waste under a Circular Economy perpectiveGasification and Pyrolyssis of plastic Waste under a Circular Economy perpective
Gasification and Pyrolyssis of plastic Waste under a Circular Economy perpective
 
Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...
Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...
Modelling, Simulation, and Computer-aided Design in Computational, Evolutiona...
 
Anatomy, and reproduction of Gnetum.pptx
Anatomy, and reproduction of Gnetum.pptxAnatomy, and reproduction of Gnetum.pptx
Anatomy, and reproduction of Gnetum.pptx
 
SCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptx
SCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptxSCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptx
SCIENTIFIC INVESTIGATIONS – THE IMPORTANCE OF FAIR TESTING.pptx
 
The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...
The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...
The cryptoterrestrial hypothesis: A case for scientific openness to a conceal...
 
Gametogenesis: Male gametes Formation Process / Spermatogenesis .pdf
Gametogenesis: Male gametes Formation Process / Spermatogenesis .pdfGametogenesis: Male gametes Formation Process / Spermatogenesis .pdf
Gametogenesis: Male gametes Formation Process / Spermatogenesis .pdf
 
El Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdf
El Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdfEl Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdf
El Nuevo Cohete Ariane de la Agencia Espacial Europea-6_Media-Kit_english.pdf
 
HAZARDOUS ENERGIES -LOTO Training Program.pptx
HAZARDOUS ENERGIES -LOTO Training Program.pptxHAZARDOUS ENERGIES -LOTO Training Program.pptx
HAZARDOUS ENERGIES -LOTO Training Program.pptx
 

Developments in regulatory requirements

  • 1. © European Compliance Academy (ECA) Developments in Regulatory Requirements Dr. Tim Sandle European Microbiology Conference 4th – 5th May, Prague
  • 2. © European Compliance Academy (ECA) Introduction  European Pharmacopoeia  United States Pharmacopoeia  ISO  PIC/S  EMEA  FDA  WHO  ICH  NHS
  • 3. © European Compliance Academy (ECA) Harmonisation  USP, EP & JP: began in 1990  Why harmonise? • Globalisation of the pharmaceutical and associated industries • Suppliers of raw materials operate globally for many products but need locally adapted test methods, SOPs etc. • Pharmaceutical manufacturers have to adapt test methods and licensing files to local requirements • Reduce costs
  • 4. © European Compliance Academy (ECA) European Pharmacopoeia
  • 5. © European Compliance Academy (ECA) European Pharmacopoeia  European Pharmacopoeia is revised and issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) (Council of Europe) • European Pharmacopoeia was first published in 1967  European Pharmacopoeia is published in two volumes. • The first volume consists of general chapters (such as the sterility test) and the second of specific monographs for materials (such as sodium heparin).  European Pharmacopoeia is issued at periodic intervals. • A primary edition. • Several supplements over a two year period.
  • 6. © European Compliance Academy (ECA) European Pharmacopoeia  Supplement 6.1: January 2008  Supplement 6.2: January 2008  Supplement 6.3: January 2008  Supplement 6.4: June 2008  Supplement 6.5: June 2008  Supplement 6.6: July 2008  Supplement 6.7: September 2009  Supplement 6.8: January 2010  7th edition: January 2011
  • 7. © European Compliance Academy (ECA) European Pharmacopoeia  Sterility Testing • Supplement 6.3: • New chapter 5.1.9 ‘Guidelines for using the test for sterility’  Section of text deleted from 2.6.1  To allow harmonisation with USP  Relates to test method and method validation • 2.6.1 is now almost fully harmonised with USP <71>  Changes: precautions against microbial contamination, culture media and incubation temperatures, method suitability test, main test method, minimum number of items to be tested.  “Residual differences” with USP: rinse fluids; volume of products tested; number of containers of product to be tested; and acceptance criteria. • Supplement 6.3: • Reference added to indicate harmonization process
  • 8. © European Compliance Academy (ECA) European Pharmacopoeia  Non-sterile products #1 • Supplement 6.3: • Harmonisation with USP for: » Microbiological examination of non-sterile products: microbial enumeration tests (2.6.12) » Microbial examination of non-sterile products: test for specified micro-organisms (2.6.13) » Microbial quality of non-sterile pharmaceutical preparations and substances for pharmaceutical use (5.1.4) - With 2.6.12 and 2.6.13, these chapters are now interchangeable in the ICH regions (Q4B Annex 4A): JP & USP
  • 9. © European Compliance Academy (ECA) European Pharmacopoeia  Non-sterile products #2 • Supplement 6.5:  A negative control now required when verifying the performance of the media AND also when testing products.  With 2.6.13: - E. coli has been deleted as an indicative strain for XLD agar since it grows with difficulty on this medium - Clostridia: the description of the test has been reworded Section 4-6-1 reads: “Divide the sample into 2 portions of at least 10 ml”. The wording has been included because a volume each of the treated and of the untreated sample must be transferred to a container with reinforced medium for clostridia. - For any suspect positive Clostridia an ID test is required in order to distinguish Clostridia from any facultative anaerobic Bacillus species
  • 10. © European Compliance Academy (ECA) European Pharmacopoeia Non-sterile products #3  Supplement 6.5:  2.6.13  A maximum incubation time of 72 h has been added (previous incubation time of exactly 48 h: too stringent)  Recommended solutions and culture media: the statement “Other media may be used if they have similar growth promoting and inhibitory properties” has been reworded because it had been considered misleading. Revised wording: “Other media may be used provided that their suitability can be demonstrated”.
  • 11. © European Compliance Academy (ECA) European Pharmacopoeia  Water testing • Supplement 6.3: • WFI 0169 and Purified Water 0008  5-day incubation time has been replaced by a requirement of not less than 5 days  Addition of criteria for growth promotion of the R2A medium used for microbiological monitoring (similar to media listed in 2.6.12 / 2.6.13)
  • 12. © European Compliance Academy (ECA) European Pharmacopoeia  Bacterial Endotoxins (2.6.14) • Supplement 6.6:  A number of clarifications have been included. - For the calculation of the endotoxin limit, the maximum recommended concentration is no longer defined for a single hour period but for a bolus dose.  A new chapter ‘Test for bacterial endotoxins: guidelines’ (5.1.10). - Not part of pharmacopoeial harmonisation - Deleted from the 2.6.14 chapter and included in part 5 of the European Pharmacopoeia.
  • 13. © European Compliance Academy (ECA) European Pharmacopoeia  Pyrogens / Endotoxin • For 7th edition:  General guidance - EU Directive 86/609/EC - Use of an in vitro method (the LAL test) as a preferred alternative to the pyrogen test in rabbits for a number of products (mainly blood products)  2.6.14 - Gel-clot technique. The number 4 has been added to the following statement:……”Determine the geometric mean end- point concentration by calculating the mean of the logarithms of the end-point concentrations of the 4 dilution series, take the antilogarithm of this value, as indicated by the following expression:………”
  • 14. © European Compliance Academy (ECA) European Pharmacopoeia  New monograph: MAT • Supplement 6.7: • An new monograph has been published. This is 2.6.30 Monocyte- activation test. • The monocyte activation test (MAT) is possible replacement for the rabbit pyrogen test and can potentially be used in conjunction with the LAL test.
  • 15. © European Compliance Academy (ECA) European Pharmacopoeia  Aspergillus brasiliensis • Supplement 6.8:  In relation to monographs 2.6.1 and 2.6.12  Strain ATCC 16404, formerly Aspergillus niger has been reclassified, following a polyphasic study, as Aspergillus brasiliensis
  • 16. © European Compliance Academy (ECA) European Pharmacopoeia  2.6.21. Nucleic acid amplification techniques • Supplement 6.8:  A validation guideline for the quantification of B19 virus DNA in plasma pools
  • 17. © European Compliance Academy (ECA) European Pharmacopoeia  Biological Indicators • For 7th edition:  Biological indicators (5.1.2)  Names of organisms have been changed to be in line with current taxonomic nomenclature  Alignment with EN ISO 11138 (Sterilization of health care products - Biological indicators)
  • 18. © European Compliance Academy (ECA) European Pharmacopoeia  Revision of EP chapter 5.1.6. Alternative Methods for Control of Microbiological Quality • Describes alternative methods for the control of microbiological quality. • Qualitative, quantitative and identification tests and guidance for using validation criteria. • Technology overviews including risk-benefit analysis and an annex describing an example of a detailed protocol for the validation of an alternative method using bioluminescence techniques.
  • 19. © European Compliance Academy (ECA) United States Pharmacopoeia Recent changes
  • 20. © European Compliance Academy (ECA) United States Pharmacopoeia USP33 2nd Supplement (October 2010) <1072> Disinfectants and Antiseptics  Classification of Disinfectants  Selection of a Disinfectant for Use in a Pharmaceutical Manufacturing Environment  Theoretical Discussion of Disinfectant Activity  Mechanism of Disinfectant Activity  Microbial Resistance to Disinfectants  Disinfectant Challenge Testing  Disinfectants in a Cleaning and Sanitisation Program
  • 21. © European Compliance Academy (ECA) United States Pharmacopoeia Proposed changes
  • 22. © European Compliance Academy (ECA) United States Pharmacopoeia  USP <1231> ‘water’ • Under revision • Tables of recommendation action limits are likely to be deleted
  • 23. © European Compliance Academy (ECA) United States Pharmacopoeia  USP <1116> under review • Action levels for EM likely to be replaced by frequency tables  E.g. Isolator, incidence rate of <0.1%  E.g. ISO Class 5, incidence rate of <1%
  • 24. © European Compliance Academy (ECA) United States Pharmacopoeia  USP <1113> Microbial Identification (USP35-NF30) • Title change • Microbial Characterization, Identification, and Strain Typing • The chapter provides general information on available microbial identification methods, selection of appropriate methods for use, and verification of these methods • Emphasis on phenotypic and genotypic methods • Trending microflora
  • 25. © European Compliance Academy (ECA) United States Pharmacopoeia  <85> Bacterial Endotoxins Test • on the basis of an FDA recommendation, change the calculation of the limit for endotoxins in products dosed by body surface area, appearing in non harmonized footnote 2
  • 26. © European Compliance Academy (ECA) United States Pharmacopoeia Possible changes
  • 27. © European Compliance Academy (ECA) United States Pharmacopoeia  A new monograph entitled, “Endotoxin Indicator for Depyrogenation” was proposed in Pharmacopeial Forum (34(6): 1444). • Definition of the term endotoxin indicator - “carrier (challenge vial of endotoxin or an article spiked with endotoxin) for use in depyrogenation studies.” • Description of the characterization (identification, purity) of an EI  Also: • Reference to the USP RSE • Packaging and storage • Expiration dating • Recovery tests • Disposal of endotoxin indicators.
  • 28. © European Compliance Academy (ECA) United States Pharmacopoeia  <1128> Nucleic Acid Based Techniques – Microarray (new) (USP35-NF30) • Because there is no information in USP on this subject, this general information chapter is being proposed. • This new chapter is a part of the series of information chapters describing various aspects of nucleic acid-based testing:  <1125> Nucleic Acid Based Techniques-General  <1126> Nucleic Acid Based Techniques-Extraction, Detection and Sequencing  <1127> Nucleic Acid Based Techniques-Amplification  <1129> Nucleic Acid Based Techniques-Genotyping  <1130> Nucleic Acid Based Techniques-Approaches for detecting Trace Nucleic Acids (Residual DNA Testing)
  • 29. © European Compliance Academy (ECA) ISO standards
  • 30. © European Compliance Academy (ECA) ISO ISO14968 (under review) Standard ISO14698 (Bio contamination control) is currently under review by British Standards  Part 1 General principles and methods  Part 2 Evaluation and interpretation of biocontamiantion data Aims:  Classification of cleanrooms by airborne biocontamination, including methods of measurement and the validation of sampling methods. Similar to ISO14644  Approaches to classify and monitor cleanroom surfaces.  Risk management and assessment techniques.  Establish a relationship between enumeration and the types of isolates detected  Consideration of some of the weaknesses of environmental monitoring sampling methods
  • 31. © European Compliance Academy (ECA) ISO  ISO 14644 (under review) • Primary change proposed is a new method for cleanroom classification • Current standard determines the number of particle counter locations in a cleanroom using a formula based on the square root of the surface area of the cleanroom in cubic metres. • The proposed change is move to classification using a table with a formula for intermediate classes (a ‘return’ to the old FS209E).
  • 32. © European Compliance Academy (ECA) ISO  ISO 21501 (in place) • Calibration of particle counters  Size calibration  Verification of size setting  Counting efficiency  Size resolution  False count rate  Concentration limit  Sampling flow rate  Sampling time  Sampling volume • Many older model particle counters will not meet the new standard.
  • 33. © European Compliance Academy (ECA) PIC/S and EMA
  • 34. © European Compliance Academy (ECA) PIC/S  PIC/S inspection guides • ‘Validation of Aseptic Processes’ (PI 007-5)  That media fills should be run for a similar length of time as product fills;  The number of containers filled should be close to the commercial batch size;  The frequency of re-qualifications is a minimum of six-monthly;  There is considerable emphasis on the selection of the appropriate culture medium, including being able to demonstrate growth promotion (as an aside, due to concerns with TSEs in Europe some companies have moved away from bovine based media and towards vegetable peptones);  The incubation conditions are established as: - “incubate at 20-25°C for a minimum of 7 days followed immediately, or after a first reading, by incubation at 30-35°C for a total minimum incubation time of 14 days”
  • 35. © European Compliance Academy (ECA) PIC/S  PIC/S inspection guides • PIC/S Document 007-4 ‘Recommendation on the Validation of aseptic processes’ has been updated • PIC/S guidance on EU GMP Annex 1  Cleanrooms and clean air device classification; and media simulation trials.
  • 36. © European Compliance Academy (ECA) EMA  The EMA has published some questions and answers concerning the use of Process Analytical Technology (PAT) on their website: http://www.gmp-compliance.org/eca_news_1385_5940,6080,6077,6095,6
  • 37. © European Compliance Academy (ECA) FDA
  • 38. © European Compliance Academy (ECA) FDA  FDA draft Process Validation Guidance • FDA’s current thinking on process manufacture • Reference to ICH Q8, Q9 and Q10, particularly the product lifecycle approach. • Main sections : process design, process qualification and continued process verification.
  • 39. © European Compliance Academy (ECA) FDA  The FDA have ‘adopted’: • three annex documents to ICH Q4B (4A, 4B and 4C). • The annexes relate to the microbiological control of non-sterile doses.
  • 40. © European Compliance Academy (ECA) WHO and NHS
  • 41. © European Compliance Academy (ECA) WHO  New publications / updates: • ‘WHO Expert Committee on Specifications for Pharmaceutical Preparations’. • WHO Good Practices for Pharmaceutical Quality Control Laboratories  Guide to: - Management, infrastructure, materials, working procedures, and safety • Annex 4 “Good Manufacturing Practices for Sterile Pharmaceutical Products”  To come in line with ISO 14644-1
  • 42. © European Compliance Academy (ECA) NHS  Monitoring hospital and cleanroom gowns • The UK NHS have a useful illustrated guide to monitoring cleanroom gowns for hospital pharmacies (EU GMP Grade B environments). The guide contains some useful pointers about selecting the locations for the microbiological contact plate monitoring and frequencies of testing.
  • 43. © European Compliance Academy (ECA) Thank You www.pharmig.blogspot.com

Editor's Notes

  1. Because r2A, 5 day v low for PW
  2. Sim to changes for sterility chapter bolus dose, an amount of IV medication administered rapidly to decrease the response time or to be used as a loading dose prior to an infusion
  3. Whole blood test
  4. For sterility and micro enumeration tests
  5. Rapid methods chapter under revision
  6. Could become a new USP chapter Treating EI like BI
  7. This standard is not very well known
  8. Big reach for ICH Q9
  9. Global reach of ISO 14644 WHO was first to introduce media fills in 1973